Dr. Meinrad Lugan

Dr. rer. nat. Meinrad Lugan, born in Oberkirch in 1964, married, one son, studied chemistry at the Albrecht-Ludwigs-University of Freiburg. He was subsequently head of the advanced organic internship of the Institute for Organic chemistry and biochemistry in Freiburg. At the same time he worked as a consultant for the chemical industry with the focus on genetic engineering and safety.

In 1994 he took over the position of head of development for a production location of the BUCK Group in the new federal states and was soon appointed as an authorized signatory and divison manager, with responsibility for the internationalization of the product range, consisting of special chemicals and production plants. From 1998 until his appointment Dr. Lugan was the managing director in the Metall-Chemie Group with the production focuses on fine chemicals, intermediates and pharmaceuticals for the worldwide market (among others fungicides, antibiotics and preparations for oncology).

In October 2000 he was appointed a member of the Management Board of B. Braun Melsungen AG. In April 2005 Dr. Lugan was moreover appointed Chief-Knowledge-Officer of B. Braun Melsungen AG.

Since March 2006 he has been a member and since April 2007 chairman of the Executive Board of the Federal Association of Medical Technology (BVMed). Dr. Lugan was confirmed in this office for a further two years in April 2018.

Since 2005 Dr. Meinrad Lugan has been an Executive Board member at the European MedTech Umbrella Association EUCOMED, unifying with EDMA to MedTech Europe in November 2016, as well as Board member of GS1 global (Barcodes, UDI). In November 2017 Dr. Lugan was elected as Treasurer and Member of the Operations Management Committee of MedTech Europe.

New Medical Device Regulation – an obstacle to progress
On May 25 th , 2017, a new era began. The date marks the beginning of the Medical Device Regulation, the MDR in short. It provides a new framework for the certification of medical devices in Europe and is supposed to increase the transparency of the approval and application of medical devices, as well as to improve patient safety. New guidelines are challenging for all parties involved Patient safety is always of utmost priority; everybody agrees on this goal. However, with the new EU legal framework, we, in the medical technology industry, are faced with existential challenges: New clinical requirements as well as comprehensive documentation and reporting obligations will result in an increased bureaucracy. This also threatens to overstrain the notified bodies, which will be intensified through the decline in the total number of bodies and also through the loss of the British notified bodies in the course of Brexit. A lack of implementation regulations due to delayed detail regulations of the MDR significantly reduce the three-year transitional period for companies’ implementation. In my opinion, this represents a very critical situation for the medium-sized MedTech sector. But it is not just the medical technology companies that are affected by the current developments: Patients’ immediate access to modern procedures, devices, and examination methods will be made more difficult, and innovation will be delayed. Pragmatic solutions for a stronger culture of progress A development that I see as very critical, considering that our goal is to bring medical progress to patients more quickly. Meaning there is a stronger culture of progress in patient care through new technical solutions, a positive atmosphere for medical and technical progress, and a quicker transfer of research findings. To expedite this development and to protect and improve the health of people all around the world, we need...